New heat treatment could zap small breast tumors without surgery
NCT ID NCT04389216
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a device that uses heat (radiofrequency ablation) to destroy small breast tumors (less than 2 cm). Thirty women with early-stage breast cancer received the treatment to see if it could safely eliminate the tumor. The goal was to find a less invasive option than standard surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiofrequency ablation device (cool-tip electrode)
- What this could lead to
- If successful, this could offer a less invasive treatment option for small breast tumors, potentially reducing the need for surgery.
- What could go wrong
- This was a small, early-stage study with only 30 participants. The results may not apply to all breast cancer patients, and there is a risk of incomplete tumor destruction or side effects from the procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
May 2020
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Infiltrating ductal carcinoma according the biopsy of the breast, * Tumor visible by ultrasound, smaller than 2 cm, * Located \> 1 cm from the chest wall and the skin. Exclusion Criteria: * Personal antecedents of breast cancer * Multifocality or intraductal carcinoma * Lobular infiltrating carcinoma * Neoadjuvant therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer female are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny clip spare breast cancer patients full lymph node removal?
- Can young breast cancer patients still have children? a new study investigates
- Can chemotherapy harm the thyroid? a new study investigates
- A blood test for breast cancer? the future of screening may be in your vein
- Can early sexual health counseling transform breast cancer recovery?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?